RTP Mobile Logo
Melanoma Update, Issue 1, 2021 (Audio Program)
Released February 2021

Featuring perspectives from Drs Michael A Davies and Karl D Lewis. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of melanoma.

    LEARNING OBJECTIVES

    • Identify patients after the surgical removal of primary melanoma for whom adjuvant therapy should be considered, and counsel them regarding the risks and potential benefits of existing and recently approved systemic approaches.
    • Consider age, performance status and other disease-related factors in the selection of first- and later-line therapy for patients with metastatic BRAF wild-type or BRAF-mutated melanoma.
    • Use available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic melanoma with a BRAF tumor mutation.
    • Recognize the FDA approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for patients with unresectable or metastatic melanoma with BRAF V600 tumor mutations, and consider how the availability of this strategy affects current therapeutic algorithms.
    • Appreciate current evidence informing the selection of therapy for patients with advanced melanoma with BRAF mutations and brain metastases.
    • Consider the adverse events associated with immune checkpoint inhibitors, targeted therapies and other systemic treatments for melanoma, and offer supportive management strategies to minimize side effects.
    • Recall available and emerging data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, targeted therapy, other immunotherapies) for advanced melanoma, and counsel appropriate patients about clinical trial availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 3.5 (audio) and 3.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide sets, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MelanomaUpdate121/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/MelanomaUpdate121/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MelanomaUpdate121/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/MelanomaUpdate121.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Michael A Davies, MD, PhD
    Professor and Chair, Department of Melanoma Medical Oncology
    Professor, Departments of Translational Molecular Pathology, Genomic Medicine and Systems Biology
    Anne and John Mendelsohn Chair in Cancer Research
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Apexigen, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Novartis, Roche Laboratories Inc.

    Karl D Lewis, MD
    Professor, Department of Medicine
    Division of Medical Oncology
    Director, Cutaneous Oncology Program
    University of Colorado Cancer Center
    Aurora, Colorado

    Advisory Committee: Eisai Inc, Incyte Corporation, Merck, Regeneron Pharmaceuticals Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Merck, Moderna, Nektar, OncoSec Medical, Replimune.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Array BioPharma Inc, Genentech, a member of the Roche Group, and Novartis.

    Release date: February 2021
    Expiration date: February 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close